Montana Patent of the Month – May 2023
HipK4, a member of the homeodomain-interacting protein kinase (HipK) family of proteins, has gained attention for its potential therapeutic benefits in treating certain cancers and spermiogenesis. HipK proteins are known for their function in the regulation of numerous signal pathways required to develop healthy tissues. Unfortunately, they may also play a role in the development and progression of certain diseases.
Vibliome Therapeutics, LLC has developed a selective inhibitor of HipK4 and pharmaceutically acceptable compositions containing it in order to treat these diseases. Their compositions are formulated using pharmaceutically acceptable carriers, adjuvants, and vehicles that do not destroy the inhibitor’s pharmacological activity. These may include ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, buffer substances, water, salts or electrolytes, polyethylene glycol, and wool fat. The dosage and delivery is dependent on the disease and patient in question.
Vibliome Therapeutics is a clinical stage company focused on the design of Type II inhibitors that lock kinase targets in an inactive conformation. Through this approach, the company hopes to support precision medicine approaches for cancer and other diseases where selective kinase targeting is needed. They currently have three core programs in place including:
- Targeting PLK4 to fight cancers including breast cancer – in Lead Optimization stage
- Targeting RIPK2 to fight cancers including late-stage prostate cancer – in Lead Optimization stage
- Targeting Single-Target Inhibitor Combinations which will combine Type I and Type II inhibitors for oncology indications.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.